Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
24.43%
Operating Margin
9.54%
Net Margin
-13.05%
Efficiency Metrics
Revenue per Expense Ratio
1.11
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
22.35%
Income Tax Rate
90,000,000.0%
EPS
-6.0900000000
Balance Sheet Analysis
Current Ratio
2.13
Cash Ratio
1.60
Working Capital
$219.85M
Debt to Equity
3,461,322,000.0
Debt to Assets
99.97%
Equity Ratio
-7.54%
Cash Flow Analysis
Operating Cash Flow Ratio
1.05%
Free Cash Flow Ratio
-9.00%
CapEx to Revenue
10.05%
Dividends Paid
$14.94M
Stock Buybacks
$168.00K
Total Shareholder Returns
$15.11M
Cash Position Change
-44.31%
Key Takeaways (2023 FY)
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
10.21%
Net Income
-26.54%
EPS
85.18%
Operating Income
71.06%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
63.79%
Operating Cash Flow
-63.31%
Free Cash Flow
121.37%
Balance Sheet Health
Assets
-11.62%
Debt
-11.35%
Book Value per Share
81.21%
Inventory
-4.59%
Shareholder Returns
Dividends per Share
-87.01%
Shares Outstanding
826.44%
Long Term Trends
3Y Revenue/Share
-98.67%
5Y Revenue/Share
-99.71%
3Y Dividend/Share
-99.74%
5Y Dividend/Share
-99.95%